Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
作者信息
Consuegra-Sánchez Luciano, Sanchis Juan, Núñez Julio, Cascón José Domingo, Villegas Manuel, Picó Francisco
出版信息
Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):378-80. doi: 10.1016/j.recesp.2011.05.024. Epub 2011 Aug 12.
PMID:21840109
Abstract
摘要
相似文献
1
Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):378-80. doi: 10.1016/j.recesp.2011.05.024. Epub 2011 Aug 12.
2
Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):678-9; author reply 679-80. doi: 10.1016/j.recesp.2012.03.006. Epub 2012 May 17.
3
Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
N Engl J Med. 2011 Mar 10;364(10):970-1. doi: 10.1056/NEJMe1014147.
4
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1087-92. doi: 10.1586/erc.12.100.
5
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.
6
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6.
7
Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Hypertens Res. 2009 Jul;32(7):575-80. doi: 10.1038/hr.2009.60. Epub 2009 May 15.
8
Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv28-30. doi: 10.1093/ndt/gfs424.
9
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Hypertens Res. 2011 Aug;34(8):935-41. doi: 10.1038/hr.2011.67. Epub 2011 Jun 9.
10
Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
Expert Opin Drug Saf. 2011 Mar;10(2):185-96. doi: 10.1517/14740338.2011.552426. Epub 2011 Jan 23.
Zotero 插件